Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 46% growth during the forecast period.
By the Disease Type - Influenza segment was valued at USD 3.44 billion in 2023
By the End-user - Adult vaccines segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 112.15 billion
Market Future Opportunities: USD 7.05 billion 
CAGR : 10.7%
North America: Largest market in 2023

Market Summary

The market is a significant sector within the healthcare industry, demonstrating continuous growth and evolution. According to various market research, the demand for travel vaccines is on the rise, with an estimated 250 million international travelers in 2020. This number is projected to reach 380 million by 2027, representing a substantial increase. Travelers' changing demographics and increased global connectivity contribute to this market expansion. For instance, an aging population and the rise of adventure tourism are key factors driving the need for diverse travel vaccines. Moreover, the market is witnessing the emergence of new vaccine types, such as combination vaccines, which offer enhanced protection against multiple diseases.
The market's dynamism is further fueled by advancements in technology, enabling the development of more effective and convenient vaccine delivery methods. For example, the use of microneedle patches and oral vaccines is gaining popularity due to their ease of administration and improved patient compliance. Despite these positive trends, challenges persist, including the lack of comprehensive vaccine coverage in some health plans and the ongoing impact of the COVID-19 pandemic on travel vaccination services. Nonetheless, the market's potential for growth remains strong, with opportunities for collaboration between stakeholders, including pharmaceutical companies, travel agencies, and healthcare providers.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore market size, adoption trends, and growth potential for travel vaccines market Request Free Sample

Travel vaccines represent a significant segment within the healthcare industry, with current market participation exceeding 20%. This figure underscores the importance of travel vaccines in safeguarding the health of globally mobile populations. Looking ahead, market expansion is anticipated to surpass 15% annually, driven by increasing awareness of disease prevention and the continuous development of innovative vaccine formulations. The market demonstrates a dynamic equilibrium between vaccine efficacy and patient compliance. For instance, in 2020, vaccine recommendations for hepatitis A and typhoid fever reached 90% and 70%, respectively, reflecting high levels of adherence. In contrast, compliance for yellow fever and rabies vaccines stood at 60% and 40%, respectively.
This disparity underscores the importance of effective vaccine education and public health initiatives to boost compliance rates and ultimately improve disease prevention. Moreover, advancements in vaccine manufacturing, cold chain management, and adjuvant systems have led to increased vaccine availability and efficacy. For example, cellular immunity responses to certain vaccines have shown promising results, leading to enhanced protection against various diseases. These advancements not only contribute to the market's growth but also improve overall traveler health and safety.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period.

The market, specifically for influenza, is experiencing substantial expansion due to several factors. The resurgence of leisure and corporate travel to pre-pandemic levels and the increasing health awareness among travelers are primary drivers. Influenza vaccines are easily accessible, as they are widely available at pharmacies, healthcare facilities, and workplaces, making administration convenient for travelers. Moreover, disease surveilla

The global travel vaccines market is booming, projected to reach $9.5 billion by 2033, driven by rising international travel and increasing vaccine awareness. Learn about market trends, key players (Pfizer, GSK, Sanofi), and regional insights in this comprehensive analysis. Recent developments include: March 2024: The UAE Ministry of Health and Prevention (MoHAP) mandated influenza vaccination for pilgrims traveling to Saudi Arabia. It was a preventive measure to protect the Hajj performers, their families, and all segments of society from infectious diseases., February 2024: The University of Kentucky’s UK Retail Pharmacies started offering travelers all the required and recommended vaccines based on their destination, including yellow fever, typhoid, and cholera., May 2023: Bavarian Nordic acquired Emergent BioSolutions’ travel vaccine portfolio for USD 274 million. The deal encompassed the acquisition of vaccines Vivotif and Vaxchora, marketed for the prevention of typhoid and cholera, respectively, and a phase III vaccine candidate for the prevention of the chikungunya virus.. Key drivers for this market are: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Potential restraints include: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Notable trends are: The Hepatitis A Segment is Expected to Witness Significant Growth During the Forecast Period.

The global travel vaccines market was valued at USD 4 billion in 2023 and is projected to reach USD 8.1 billion by 2032, registering a CAGR of 9.5% during the forecast period (2024-2032).
Report Scope:

The global travel vaccines market is booming, projected to reach $9.74 billion by 2033 with a CAGR of 8.33%. Driven by increased international travel and demand for preventative healthcare, this market sees key players like Pfizer and Sanofi leading innovation. Learn more about market trends and growth forecasts. Recent developments include: March 2024: The UAE Ministry of Health and Prevention (MoHAP) mandated influenza vaccination for pilgrims traveling to Saudi Arabia. It was a preventive measure to protect the Hajj performers, their families, and all segments of society from infectious diseases., February 2024: The University of Kentucky’s UK Retail Pharmacies started offering travelers all the required and recommended vaccines based on their destination, including yellow fever, typhoid, and cholera., May 2023: Bavarian Nordic acquired Emergent BioSolutions’ travel vaccine portfolio for USD 274 million. The deal encompassed the acquisition of vaccines Vivotif and Vaxchora, marketed for the prevention of typhoid and cholera, respectively, and a phase III vaccine candidate for the prevention of the chikungunya virus.. Key drivers for this market are: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Potential restraints include: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Notable trends are: The Hepatitis A Segment is Expected to Witness Significant Growth During the Forecast Period.

The global travel vaccines market size is projected to increase from USD 4.91 billion in 2025 to USD 12.62 billion by 2035, with CAGR growth above 9.9%. Major industry participants include Sanofi, Pfizer, GSK, Merck, Bavarian Nordic, driving growth and innovation in the market.

The coronavirus (COVID-19) pandemic caused serious disruptions to the travel industry worldwide. When surveyed in March 2021, respondents from the United Kingdom declared that having received a vaccine was the most important factor when deciding whether to go on a vacation, with ** percent stating that this was the case.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc